Grifols, S.A. American Depositary Shares GRFS
i
Market datapartial · fetched 2026-11-12T00:52:21.556Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:07.772523703Z
FundamentalsAlpha Vantage · unavailable
Grifols, S.A. American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 15.17 | 361.7% | 78.1% | 7.42 | 216.6% | 22.0% |
| 30Δ | 7.88 | 196.0% | 17.7% | |||
| 35Δ | 10.31 | 161.4% | 21.6% | 8.20 | 176.8% | 14.6% |
| 40Δ | 9.87 | 144.7% | 17.0% | 8.47 | 158.1% | 11.9% |
| 45Δ | 9.42 | 128.1% | 12.3% | 8.74 | 139.5% | 9.2% |
| 50Δ | 9.01 | 121.5% | 6.6% | |||
| 55Δ | 9.22 | 118.9% | 5.7% | |||
| 60Δ | 9.43 | 116.3% | 4.8% | |||
| 65Δ | 9.64 | 113.7% | 4.0% | |||
| 70Δ | 9.85 | 111.0% | 3.1% | |||
| 75Δ | 10.12 | 109.9% | 2.3% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 15.17
- IV
- 361.7%
- B/E move
- 78.1%
- Pseudo strike
- 7.42
- IV
- 216.6%
- B/E move
- 22.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.88
- IV
- 196.0%
- B/E move
- 17.7%
35Δ
- Pseudo strike
- 10.31
- IV
- 161.4%
- B/E move
- 21.6%
- Pseudo strike
- 8.20
- IV
- 176.8%
- B/E move
- 14.6%
40Δ
- Pseudo strike
- 9.87
- IV
- 144.7%
- B/E move
- 17.0%
- Pseudo strike
- 8.47
- IV
- 158.1%
- B/E move
- 11.9%
45Δ
- Pseudo strike
- 9.42
- IV
- 128.1%
- B/E move
- 12.3%
- Pseudo strike
- 8.74
- IV
- 139.5%
- B/E move
- 9.2%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.01
- IV
- 121.5%
- B/E move
- 6.6%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.22
- IV
- 118.9%
- B/E move
- 5.7%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.43
- IV
- 116.3%
- B/E move
- 4.8%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.64
- IV
- 113.7%
- B/E move
- 4.0%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.85
- IV
- 111.0%
- B/E move
- 3.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.12
- IV
- 109.9%
- B/E move
- 2.3%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 59.73% | |
| 61.89% | |
| 58.06% | |
| 53.22% | |
| 73.53% | |
| 47.18% | |
| 61.54% | |
| 42.85% | |
| 54.77% | |
| 44.86% | |
| 52.85% | |
| 74.34% | |
| 98.91% | |
| 99.86% | |
| 162.48% | |
| 54.77% | |
| 67.18% | |
| 66.88% | |
| 64.00% | |
| 65.77% | |
| 66.99% | |
| 113.31% | |
| 123.66% | |
| 54.76% | |
| 55.64% | |
| 62.47% | |
| 59.62% | |
| 51.45% | |
| 56.33% | |
| 49.61% | |
| 43.95% | |
| 55.91% |
Drug Manufacturers - General
GSK
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related…
More →JNJ
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a…
More →LLY
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125…
More →MRK
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in…
More →NVO
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in…
More →NVS
Description unavailable
More →